Literature DB >> 34755213

D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity.

Manojit Bhattacharya1, Srijan Chatterjee2, Ashish Ranjan Sharma3, Govindasamy Agoramoorthy4, Chiranjib Chakraborty5.   

Abstract

The progression of the COVID-19 pandemic has generated numerous emerging variants of SARS-CoV-2 on a global scale. These variants have gained evolutionary advantages, comprising high virulence and serious infectivity due to multiple spike glycoprotein mutations. As a reason, variants are demonstrating significant abilities to escape the immune responses of the host. The D614G mutation in the S-glycoprotein of SARS-CoV-2 variants has shown the most efficient interaction with the ACE2 receptor of the cells. This explicit mutation at amino acid position 614 (aspartic acid-to-glycine substitution) is the prime cause of infection and re-infection. It changes the conformation of RBD and cleavage patterns S-glycoprotein with higher stability, replication fitness, and fusion efficiencies. Therefore, this review aims to provide several crucial pieces of information associated with the D614 mutational occurrence of SARS-CoV-2 variants and their infectivity patterns. This review will also effectively emphasize the mechanism of action of D614G mutant variants, immune escape, and partial vaccine escape of this virus. Furthermore, the viral characteristic changes leading to the current global pandemic condition have been highlighted. Here, we have tried to illustrate a novel direction for future researchers to develop effective therapeutic approaches and counterweight strategies to minimize the spread of COVID-19.Key points• D614G mutation arises within the S-glycoprotein of significant SARS-CoV-2 variants.• The D614G mutation affects infection, re-infection, cleavage patterns of S-glycoprotein, and replication fitness of SARS-CoV-2 variants.• The D614G mutation influences the immunity and partial vaccine escape.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  D614G mutation; Mutational changes; S-glycoprotein; SARS-CoV-2; Variants

Mesh:

Substances:

Year:  2021        PMID: 34755213      PMCID: PMC8578012          DOI: 10.1007/s00253-021-11676-2

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


Introduction

The SARS-CoV-2 infections cause a quick increase of COVID-19 cases to develop a severe risk to human health worldwide. Hence, it is vital to understand the virus’s mutational changes and rapid evolution. It is also crucial to know the impact of novel vaccine development, diagnostic tests, antiviral drugs pathogenesis, resistance, and immune responses (Chellapandi and Saranya 2020; Sanjuán and Domingo-Calap 2016). So, continuous monitoring and accurate analysis of the evolutionary phenomenon of SARS-CoV-2 are crucial to distinguish the definite genetic changes and variations leading to the virulence and transmissibility of the virus (Leopold and Busby 2020; Mercatelli and Giorgi 2020). During the SARS-CoV-2 virus outbreak, the genetic variations have evolved at a faster rate. Within several variations, a conversion of the A (adenine) nucleotide at genome locus of 23,403 to a G (guanine) occurred, and it has been recognized as the most prevalent clade SARS-CoV-2 virus (Korber et al. 2020b). Such nucleotide changes arose in March 2020 at a low frequency, but they became rapidly extended and considered an utmost infinite clade by April–May 2020. It also offered an advantage of selective fitness during the outbreaks. A report showed that the spike glycoprotein with G at the position of 614 (S-G614) linking maximum viral loads was noted in the upper respiratory tract of infected patients with low disease severity (Korber et al. 2020b). It is also noted that engineered viruses ensuring S-G614 also show a significant infection rate than the viruses with S-D614 (Clay et al. 2014; Plante et al. 2021). This mutation is localized in the exterior part of the RBD (receptor binding domain) region of the spike glycoprotein (Fig. 1). Therefore, the same affinities for binding S-D614 and S-G614 to the ACE2 (angiotensin-converting enzyme 2) receptor were also reported (Yurkovetskiy et al. 2020; Zhang et al. 2020a). Significantly, the convalescent sera from COVID-19 patients might neutralize the mutated S-D614 and the S-G614-pseudotyped viruses with equivalent efficacies (Korber et al. 2020b; Weissman et al. 2021).
Fig. 1

Schematic diagram of the location of D614G amino acids where mutation occurs in S-glycoprotein

Schematic diagram of the location of D614G amino acids where mutation occurs in S-glycoprotein A research report supported the chances that the D614G nucleotide substitution confers higher infectivity and transmissibility without better binding affinities to ACE2 receptors or over increased escape of immune surveillance mechanisms (Cheng et al. 2021). It is also essential that multiple characteristic changes are observed in SARS-CoV-2 variants due to the D614G mutant (Table 1). Explaining the mechanism of higher infectivity by D614G mutation containing SARS-CoV-2 virus is critical to understanding the prevalence for developing an effective treatment approach for virus-infected patients.
Table 1

Characteristics changes of SARS-CoV-2 between the wild-type strain and D614G mutant variant

Sl. NoSeveral characteristics of the SARS-CoV-2 virusD614 at S-proteinG614 at S-proteinReference
1Binding affinity with the ACE2 receptorLesser than G614Much more greater than D614(Ozono et al. 2021)
2Spike protein densityLessMore(Zhang et al. 2020a)
3Spike protein stabilityLess stableGreater stability compared to D614(Jackson et al. 2021)
4Spike protein cleavage patternLess resistant to cleavage than the G614More resistant to cleavage(Daniloski et al. 2021)
5Conformation of the RBDConfirmation varies from G614Preferably stays in the open conformation(Yurkovetskiy et al. 2020)
6Infectivity rateLower than the mutant strainMuch higher(Zhang et al. 2021)
7Disease severitySame in both the variantsSame in both the variants(Korber et al. 2020b; Volz et al. 2021)
8Mortality rateSame in both the variantsSame in both the variants(Volz et al. 2021)
9RMSD study of S-protein after interaction with ACE2 receptor1.09 ± 0.04 nm1.26 ± 0.1 nm(Kwarteng et al. 2021)
10RMSF study of S-protein after interaction with ACE2 receptorLess flexible compared to G614Structurally more flexible(Kwarteng et al. 2021)
11Replication fitnessLower than G614Greater(Hou et al. 2020; Korber et al. 2020b; Yurkovetskiy et al. 2020; Zhang et al. 2020a)
12S1 domain sheddingGreater sheddingThe shedding is reduced compared to D614 S(Zhang et al. 2020a)
13Stability of the S1 and S2 interfaceLess stable than G614Much more stabilized(Fernández 2020)
14Retention of S1 subunitLesser retention compared to G614Have more retention capacity(Zhang et al. 2020a)
15Viral loadLower than G614Higher(Korber et al. 2020b; Volz et al. 2021)
16Fusion efficiencyLower than G614Higher(Zhang et al. 2021)
Characteristics changes of SARS-CoV-2 between the wild-type strain and D614G mutant variant In this manuscript, we have discussed the D614G mutation using different points, such as the distribution of D614G mutation in all significant variants of this virus. An implication of the mutation in different variants such as B.1.1.7 (alpha) variant, B.1.351 (beta) variant, P.1 (gamma) variant, B.1.525 (eta) variant, B.1.526 (iota) variant, P.2 variant, and B.1.427/B.1.429 (epsilon) variants has also been illustrated. Moreover, we have discussed the D614G mutation that helps in the infectivity and re-infectivity. The molecular mechanism of action of D614G mutant variants is illustrated very extensively. Finally, we demonstrate the immune escape and partial vaccine escape due to this mutation. At the same time, to illustrate the molecular mechanism of action of D614G mutant variants, we have presented some essential points which are first, D614G mutant and RBD conformation; second, S-protein cleavage pattern and D614G mutation; third, S-protein stability and D614G mutation; fourth, D614G mutation and S-protein volume; and fifth, D614G mutation activity on human ACE2 receptor protein.

The presence of D614G far and wide

The majority of the SARS-CoV-2 genome contained the aspartic acid in spike protein’s 614th position depicting the trimeric structure in a closed form (Fig. 2), as reported till February 2020. Since then, the prevalence of G614 has been noticed in the SARS-CoV-2 isolates (Daniloski et al. 2021). According to the GISAID’s EpiCoV database, 72% (22,103) of the SARS-CoV-2 genome analysis highlighted the presence of G614 mutation by early June 2020 (Shu and McCauley 2017). Within a short tenure, the G614 mutation became particularly dominant worldwide (Table 2) (Hadfield et al. 2018). According to epidemiological reports, the WHO classified the variants under two categories: the variant of interest (VOI) and the variant of concern (VOC). The CDC also followed the same. The VOIs and VOCs are classified based on viral transmission rate, virulence, vaccine efficacy, etc. (Aleem et al. 2021; Chakraborty et al. 2021). These variants originating from a different country of SARS-CoV-2 have shown the sequence similarity of S-protein, which contains D614G mutation (Table 3).
Fig. 2

D614G mutation location in the 3D model of S-glycoprotein and different conformational states of S-glycoprotein. A 3D model of S-glycoprotein stating the location of D614G mutation. B Open conformation of S-glycoprotein. C Closed conformation of S-glycoprotein. Researchers noted that D614G mutation favors the open conformation of S-glycoprotein and thus helps more interaction with the hACE2 receptor, which causes more infection and re-infection

Table 2

Data showing the country-wise frequency and date of the first report of the D614G mutant variant of SARS-CoV-2 worldwide

SL. NoCountry nameFrequency of D614G mutationDate of first report
1India20,2242020–01-12
2Bangladesh12142020–04-08
3Australia13,1772020–01-25
4Iran2052020–01-06
5Italy30,9442020–02-06
6South Africa46762020–01-05
7USA350,9092020–01-03
8Spain32,5902020–02-14
9South Korea53722020–09-05
10United Kingdom222,2742020–01-05
11Brazil20,2542020–02-25
12China3142020–01-24
13Mexico12,1342020–01-02
14New Zealand7752020–03-02
15Netherlands38,3312020–01-08
16Pakistan1812020–05-03
17Canada55,7142020–01-01
18Germany109,2122020–02-08
19England148,6202020–02-03
20Japan61,5962020–02

Source: https://coval.ccpem.ac.uk/mutations

Table 3

Sequence similarity of S-protein from different mutant variants of SARS-CoV-2, containing D614G mutation

SL. NoName of the variantOriginSimilarity with D614G variant (%)
1B.1.525UK/Nigeria0.25
2B.1.526USA0.94
3B.1.617.1India0.21
4B.1.617.2India12.59
5P.2Brazil0.17
6P.3Philippines/Japan0.01
7B.1.427USA0.64
8B.1.1.7UK35.40
9B.1.351South Africa0.99
10B.1.427USA0.64
11P.1Japan/Brazil2.30

Source: https://cov-spectrum.ethz.ch

D614G mutation location in the 3D model of S-glycoprotein and different conformational states of S-glycoprotein. A 3D model of S-glycoprotein stating the location of D614G mutation. B Open conformation of S-glycoprotein. C Closed conformation of S-glycoprotein. Researchers noted that D614G mutation favors the open conformation of S-glycoprotein and thus helps more interaction with the hACE2 receptor, which causes more infection and re-infection Data showing the country-wise frequency and date of the first report of the D614G mutant variant of SARS-CoV-2 worldwide Source: https://coval.ccpem.ac.uk/mutations Sequence similarity of S-protein from different mutant variants of SARS-CoV-2, containing D614G mutation Source: https://cov-spectrum.ethz.ch

Implication of D614G in B.1.1.7 (alpha) variant

The D614G mutation in the S-protein is predominant in the virus inhabiting the upper respiratory tract. This mutation has been observed in most SARS-CoV-2 isolates worldwide (Korber et al. 2020b; Yurkovetskiy et al. 2020). Another extremely virulent strain with the presence of D614G mutation is B.1.1.7, and it was first reported in the UK (Peters et al. 2021). The D614G mutation results in forming a structural cavity between S1 and S2 interface in B.1.1.7 variant, contributing to its high transmission efficiency. However, the D614G mutation also accelerates the spike protein cleavage into S1 and S2 domains, hindering the contact between the separate chains of the spike protein complex. It also results in a robust structural rearrangement enhancing the invading capacity of this variant into the respiratory epithelial host cells (Fig. 3). This mutation also reduces the intermolecular attraction between the two subunits (S1 and S2) of the D614G strain. The D614G mutation site also serves as an effective tool for designing vaccines against B.1.1.7 strain with a very high transmissibility rate (Ostrov 2021).
Fig. 3

The schematic diagram illustrates the D614G mutation causing more infectivity. Due to this mutation, the S-protein volume increases and causes more infections

The schematic diagram illustrates the D614G mutation causing more infectivity. Due to this mutation, the S-protein volume increases and causes more infections

Effect of D614G in B.1.351 (beta) variant

The beta variant (B.1.351), also known as the beta strain, was isolated from South Africa at the end of 2020 (Tegally et al. 2021). This variant includes several mutations, including D614G. As discussed earlier, a common characteristic of this mutation is increased transmissibility; the B.1.351 strain is also reported to be highly virulent. The B.1.351 binds to the ACE2 receptor strongly (Mwenda et al. 2021; Wibmer et al. 2021). The additional mutations in the B.1.351 strain highlight that there might be some molecular basis of evolution, which is yet to be confirmed (Slavov et al. 2021), and it contributes to a greater virulence of the strain. The D614G mutation in B.1.351 variant also alters its binding affinity with hACE2 (human angiotensin-converting enzyme 2) and brings about some changes in antibody neutralization (Zhou et al. 2021b).

Importance of D614G in P.1 (gamma) variant

The gamma variant (P.1) had shown the maximum number of mutations in the spike glycoprotein compared to other variants. D614G in the spike protein outside the RBD is also present (Harvey et al. 2021; Wang et al. 2021a). This variant was first reported in Brazil at the end of 2020 and in the USA in January 2021 (Faria et al. 2021). Due to the prevalence of the D614G mutation, there is an alteration in the RBD conformation, maintaining it in an open state and an increased affinity of the variant towards the ACE2 receptor contributes to its high transmission rate.

Significance of D614G in B.1.525 (eta) variant

The eta (B.1.525) is an emerging and significant variant highlighted by the WHO when it was first reported in the USA in December 2020. This strain also possesses several mutations, notably in the S-protein, of which D614G is common. This strain only contains a single mutation in the RBD (Chakraborty et al. 2021). Eta variant demonstrates alteration in the neutralization post-vaccination and antibody treatment (Janik et al. 2021). It shows a greater transmissibility rate and virulence, a common characteristic of the D614G mutation. These characteristics affect the effectiveness of vaccines and therapeutics used for treating COVID-19 infection. It is also considered to be responsible for community infection (World Health Organization 2021; Sharun et al. 2021). Moreover, it alters the B.1.525 virion replication inside the host cells (Zhou et al. 2021a).

Association of D614G in B.1.526 (iota) variant

The iota (B.1.526) variant was isolated from the USA in November 2020. It replaces aspartic acid residue in the 614th position, and it has a significant impact on vaccine efficacy and therapeutics. As a consequence, it is known to be very detrimental to public health (West et al. 2021). On June 22, 2021, the WHO declared it as the “VOI” due to its potential to decrease neutralization efficiency, enhanced transmission efficiency, and virulence (Aleem et al. 2021). Notwithstanding the fact, we can conclude by seeing the characteristics of this variant that the D614G spike mutation plays a potential role in dominating these characteristics in this variant. These are some of the standard features possessed by the D614G variant.

Importance of D614G in P.2 (zeta) variant

Similar to B.1.525 and B.1.526, the P.2 variant has been kept in the category of “VOI” by the WHO due to its potential effect in antibody neutralization. The P.2 (zeta) variant was first reported from Brazil in April 2020 (Aleem et al. 2021). The zeta variant has few mutations, and D614G in the S-protein outside the RBD is common among them (Chakraborty et al. 2021).

Impact of D614G in B.1.427/B.1.429 (epsilon) variant

The B.1.427/B.1.429 (epsilon) variants were isolated from California, USA. The B.1.427 has a single mutation in the trimeric spike complex, namely, D614G, and it falls under the VOC category by the CDC and VOI by the WHO. The B.1.429 variant had some other mutations in the spike protein besides D614G. It was called VOI by both CDC and WHO. These variants have shown their extreme contagious nature. Due to similar mutations with the other strains, this variant also possesses the same immune and partial vaccine escape property (McCallum et al. 2021).

D614G mutation and infectivity

One of the common reasons for the SARS-CoV-2 re-infection could be the mutation of D614 to G614, as highlighted from the SARS-CoV-2 genome sequencing (Amorim et al. 2021). This mutation in the spike protein proved to be more infectious. In this mutation, the G614 indicated a higher affinity towards the ACE2 receptor and more extensive incorporation of the spike protein into the host genome (Zhang et al. 2020b). Zhang et al. also elucidated that the mutation of the aspartic acid with glycine at the 614th position is more stable and thus has a greater contagious rate. Two patients in Iran were reinfected with the virus, and the genome sequencing results indicated the D614G mutation. However, both of them did not have severe symptoms, although being affected with the mutant strain (Salehi-Vaziri et al. 2021). Another series of cases reported from Brazil also implicated the same data. The signs were not variable to a greater extent for the second time (Amorim et al. 2021). Despite the stable nature of the mutation, no noticeable symptoms were seen in the case of re-infection (Korber et al. 2020a; Zhang et al. 2020c). According to Zhang et al., the possible reason could be due to the greater incorporation of the spike protein into the host genome leading to more transmission. Nonetheless, due to some parameters, the replication inside the host was prevented to some extent. Moreover, the mutation favored to a greater extent in species inhabiting a furin-cleavage site (Zhang et al. 2020b). The cleavage at the furin site promoted the transmission to a greater extent in viral replication (Cheng et al. 2021).

Molecular mechanism of action of D614G mutant variants

The elucidated molecular mechanism lying behind the D614G mutation is yet to be explored. Certain factors based on the mutation can be explained, and they include the cleavage pattern of the spike protein, the conformation of the RBD, volume of spike protein incorporated, and strength (Fig. 3) (Jackson et al. 2021). The mutation takes place in spike protein, and as a result, it may affect the binding efficiency to the ACE2 receptor. Zhang L et al. provided plasmon resonance data implying that the S-trimeric complex of D614 and G614 shows a similar binding affinity with the ACE2 receptor (Zhang et al. 2020a). Another group of scientists made the same conclusion using the bio-layer interferometry technique (Daniloski et al. 2021).

RBD conformation and D614G mutation

According to Gobeil et al., the cryo-electron microscopic structure elucidated that the G614 variant had an altered conformation of the RBD region, which makes it highly efficient in cleaving the furin site (Gobeil et al. 2021). This cleavage, in turn, regulates the ratio of the RBD in the spike ectodomain and induces an allosteric effect on its position. Although the D614G mutation site is distant from the RBD, it still alters activity in the mutant variants. Mansbach and his colleagues have performed molecular dynamics simulation highlighting the D614G results in an open conformation of the RBD. The open-up conformation of the RBD enables the virus to infect the host because the closed conformation does not permit the ACE2 and RBD interaction (Mansbach et al. 2021). According to Weissman et al., 84% of the S-protein in the G614 strain are in “one-up” conformation and the rest “three-down” conformation (Weissman et al. 2021). The open-up conformation of the RBD in the D614G mutant strain contributes to its enhanced transmissibility into the host cells (Korber et al. 2020b). The glycine mutation at the 614th position disrupts the formation of a salt bridge between D614 and lysine residue (K854), which allows the RBD to be in the open state in the G614 variant (Cai et al. 2020; Xiong et al. 2020; Zhang et al. 2021; Zhou et al. 2020).

S-protein cleavage pattern and D614G mutation

Structurally, the S-protein is a trimeric complex. Its cleavage by a furin protease gives an S1 subunit, which contains the RBD, and the fusion complex S1/S2 at the cell surface mediates the viral entry into the host cell. The S-protein cleavage in the D614G strain interferes with the confirmation of the RBD, resulting in reduced shedding of the S1 subunit. The open conformation of the RBD in this mutant enhances its transmissibility (Yurkovetskiy et al. 2020; Zhang et al. 2020a). Another novel discovery made while modulating the S-protein cleavage pattern was the site for elastase cleavage (Bhattacharyya et al. 2020; Hu et al. 2020). Moreover, the G614 variant also possesses a more efficient cleavage at the furin site than the D614 (Gobeil et al. 2020). Daniloski et al. also reported that the G614 mutant is more insusceptible in cleavage phenomena of the S-protein than the D614 (Daniloski et al. 2021). However, Spike 614 is located next to the fusion peptide, which is somewhat near the protease cleavage site. This fact highlights the variation in the tendency or requirement of the TMPRSS2 to cleave the spike glycoprotein in the G614 strain (Korber et al. 2020b).

S-protein stability and D614G mutation

The G614 S-protein is more stable than the D614 SA cryo-EM data provided by Zhang et al., which elucidated that in the G614 Spike trimeric complex, there is a residue near the CTD2 region, which is highly oriented compared to D614. This orientation makes the G614 Spike structurally flexible, and it forms a loop, packaging the S trimer between CTD1 and NTD. The structural flexibility also helps in closing the hydrophobic region of the CTD2 domain. As a result, the S1 domain shedding is reduced (Zhang et al. 2021). It is the primary reason behind the S-protein stability in the G614 mutant. The other factors which play an essential role in S-protein stability are the interaction stability between the two domains (namely S1 and S2), the stronger interparticle attraction between the molecules of the two domains, and the greater holding capacity of the S1 domain (Fernández 2020; Zhang et al. 2020b). Mahmoudi Gomari et al. have investigated the structural stability of the spike protein in the D614G mutation using some in silico approaches and concluded that the replacement of the aspartic acid residue with glycine decreases the entropy and energy of the mutant strain compared to the wild type. The decrease is due to the incorporation of glycine, which has a very short side chain compared to aspartic acid. This, in turn, also contributes to the increase in S-glycoprotein stability in the D614G mutation (Mahmoudi Gomari et al. 2021).

D614G mutation and S-protein volume

The D614G mutation does not increase the binding efficiency of the spike protein with the ACE2 receptor. This variant’s enhanced infectivity and transmissibility rate are more because of incorporating more spike protein into the virion. Incorporating a more incredible amount of spike protein results in the reduced shedding of the S1 domain and stabilizes the S1 and S2 domains (Zhang et al. 2020a). It has been reported that the D614G mutation does not possess greater severity of the disease, but it enhances viral fitness (Korber et al. 2020b; Zhang et al. 2020c). Several factors that make the G614 mutation more stable than the D614 are the ratio of the S1 and S2 domains is weaker in the case of D614 compared to G614. Due to the lesser volume of the spike glycoprotein in the D614 variant, the intra-host replication ability is altered compared to G614 (Zhang et al. 2020a). Moreover, the increased volume of the spike glycoprotein in the D614G mutation gives it additional characteristic features, including transmissibility, virulence, antigenicity, immune escape, and partial vaccine escape.

D614G mutation and human ACE2 receptor protein

The SARS-CoV-2 virus invades the host by the interaction of S-protein with the ACE2 receptor. Besides, the spike protein interacts with some other co-receptors (Daly et al. 2020). The D614G mutation in the spike protein increases the host-invading capability of the virus due to the strong binding with the ACE2 receptor. However, the binding affinity does not have any influence on its antigenicity (Ozono et al. 2021). The spike protein is activated after cleaving it by the TMPRSS2 protease into two subunits, namely S1 and S2 (Belouzard et al. 2009; Hoffmann et al. 2020).The binding of the spike glycoprotein with the ACE2 receptor results in the shedding of the S1 domain. As a result, the S2 domain gets exposed (Belouzard et al. 2009). The site of the D614G mutation is situated in the carboxy-terminal of the S1 domain, which belongs to the exterior region of the RBD (Ogawa et al. 2020). Ozono et al. experimented with the binding affinity of the ACE2 receptor and concluded that the D614G variant has a greater binding affinity than the wild-type strain. This increased binding efficiency also makes the mutant spike protein structurally flexible (Ozono et al. 2021). The replacement of the aspartic acid residue with glycine resulted in the presence of the virus in the upper respiratory tract region, highlighting the greater infectivity rate as more viruses interact with the ACE2 receptor of epithelial cells (Fig. 3). However, the open conformation state of the spike glycoprotein does not have a more significant effect on the binding affinity with the ACE2 receptor (Mansbach et al. 2021).

Immune escape and D614G

Due to the prevalence of specific mutations in the SARS-CoV-2 isolates, “immune escape” is a significant concern for scientists now (Chakraborty et al. 2021). The re-infection of COVID-19 suggests the challenging role of the host immune system in combating the virus. As the viral replication results in mutation, the preformed antibodies may not be sufficient for viral clearance (Shi et al. 2020b). The direct effect of the D614G mutation is yet to be explored. However, the replacement of a single residue will not be a worthy cause for immune escape. The alteration in the confirmation due to this mutation may somehow change the binding affinity (Koyama et al. 2020). A SARS-CoV-2 pp assay (spike-pseudotyped particle) was conducted to examine the chances of immune escape due to the emergence of the D614G mutation, which insinuated the neutralizing effect of the antibodies against this mutation. This assay shows that the mutation does not significantly impact the immune escape but serves as a pivotal regulator to enhance viral fitness and transmissibility (Li et al. 2020). However, Kwarteng et al. reported that the D614G alters the conformation of the spike glycoprotein towards an open state. The alteration and interaction of spike protein with antibodies suggest that the D614G mutation may elevate, drop, or bring no change in the neutralization effect as it is entirely controlled by the nature of the neutralizing antibody (Kwarteng et al. 2021).

Partial vaccine escape and D614G

The evidence of re-infection had agitated everyone worldwide, leading to the question on the efficacy of administered vaccines (Zhang et al. 2020b). All the vaccines were formulated before the emergence of the G614 mutation. The epitope prediction of the HLA alleles implicated that the mutation alters the binding of the MHC (Andreatta and Nielsen 2016), and it had shown a remarkable change in the conformation of the RBD, resulting in decreased efficacy of vaccines. The change makes the variant more stable and increases antibody neutralization (Chi et al. 2020; Liu et al. 2020). Moreover, the mutation is a valuable tool for scientists to formulate the next-generation vaccines for the emerging strains since they became susceptible to the previously administered vaccines (Jeyanathan et al. 2020; Wang et al. 2021b, 2021c; Wu et al. 2021). This susceptibility has been proved by conducting several experiments on hamsters by analyzing the serum (Shi et al. 2020a). The remarkable change observed in the spike protein due to the alternation of the RBD conformation enhances the viral transmission but hardly changes its antigenicity (Yurkovetskiy et al. 2020). It is mainly responsible for getting a varying neutralizing effect on the antibodies due to this mutation.

Conclusion

The D614G mutant became predominant across the world within a brief period. All the mutant variants declared as VOI/VOC by the WHO and CDC had the D614G mutation common. The mutation occurs in the S-protein, yet it alters some of the conformations, giving some extra fitness to the virus. It brings many changes in the S-glycoprotein’s characteristic features that make the strain predominant (Fig. 4). The evolution of this strain also raises questions regarding the efficiency of the vaccine. However, studies suggest that this strain does not have a potential role in increasing the disease severity. Still, some cases of re-infection confirmed the presence of D614G mutation in the genome of these isolates. Some alteration in the spike protein gives it an enhanced transmission rate and serves as an effective tool for scientists in developing the next-generation therapeutics for treating COVID-19. The replacement of a single amino acid might not lead to immune escape to a greater extent. Still, the presence of this mutation made some variants (P.1, B.1.1.7, and B.1.427/B.1.429) more virulent. The virulence was alarming, and therefore, understanding the changes in the molecular mechanism of the variants due to D614G mutation and how it affects their virulence is a prerequisite. More studies on the changes in molecular mechanism and virulence of the variants due to the D614G mutation will help future researchers develop proper therapeutics and vaccines, helping to end the pandemic soon.
Fig. 4

A conceptual diagram illustrating the characteristics change of the SARS-CoV-2 variant due to the D614G mutation

A conceptual diagram illustrating the characteristics change of the SARS-CoV-2 variant due to the D614G mutation
  56 in total

1.  Host Genotype and Colonist Arrival Order Jointly Govern Plant Microbiome Composition and Function.

Authors:  Devin R Leopold; Posy E Busby
Journal:  Curr Biol       Date:  2020-07-16       Impact factor: 10.834

2.  Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites.

Authors:  Sandrine Belouzard; Victor C Chu; Gary R Whittaker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

3.  Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment.

Authors:  Takahiko Koyama; Dilhan Weeraratne; Jane L Snowdon; Laxmi Parida
Journal:  Pathogens       Date:  2020-04-26

4.  Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.

Authors:  Erik Volz; Verity Hill; John T McCrone; Anna Price; David Jorgensen; Áine O'Toole; Joel Southgate; Robert Johnson; Ben Jackson; Fabricia F Nascimento; Sara M Rey; Samuel M Nicholls; Rachel M Colquhoun; Ana da Silva Filipe; James Shepherd; David J Pascall; Rajiv Shah; Natasha Jesudason; Kathy Li; Ruth Jarrett; Nicole Pacchiarini; Matthew Bull; Lily Geidelberg; Igor Siveroni; Ian Goodfellow; Nicholas J Loman; Oliver G Pybus; David L Robertson; Emma C Thomson; Andrew Rambaut; Thomas R Connor
Journal:  Cell       Date:  2020-11-19       Impact factor: 41.582

5.  Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

Authors:  Daming Zhou; Wanwisa Dejnirattisai; Piyada Supasa; Chang Liu; Alexander J Mentzer; Helen M Ginn; Yuguang Zhao; Helen M E Duyvesteyn; Aekkachai Tuekprakhon; Rungtiwa Nutalai; Beibei Wang; Guido C Paesen; Cesar Lopez-Camacho; Jose Slon-Campos; Bassam Hallis; Naomi Coombes; Kevin Bewley; Sue Charlton; Thomas S Walter; Donal Skelly; Sheila F Lumley; Christina Dold; Robert Levin; Tao Dong; Andrew J Pollard; Julian C Knight; Derrick Crook; Teresa Lambe; Elizabeth Clutterbuck; Sagida Bibi; Amy Flaxman; Mustapha Bittaye; Sandra Belij-Rammerstorfer; Sarah Gilbert; William James; Miles W Carroll; Paul Klenerman; Eleanor Barnes; Susanna J Dunachie; Elizabeth E Fry; Juthathip Mongkolsapaya; Jingshan Ren; David I Stuart; Gavin R Screaton
Journal:  Cell       Date:  2021-02-23       Impact factor: 41.582

6.  Detection of B.1.351 SARS-CoV-2 Variant Strain - Zambia, December 2020.

Authors:  Mulenga Mwenda; Ngonda Saasa; Nyambe Sinyange; George Busby; Peter J Chipimo; Jason Hendry; Otridah Kapona; Samuel Yingst; Jonas Z Hines; Peter Minchella; Edgar Simulundu; Katendi Changula; King Shimumbo Nalubamba; Hirofumi Sawa; Masahiro Kajihara; Junya Yamagishi; Muzala Kapin'a; Nathan Kapata; Sombo Fwoloshi; Paul Zulu; Lloyd B Mulenga; Simon Agolory; Victor Mukonka; Daniel J Bridges
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-02-26       Impact factor: 17.586

7.  Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies.

Authors:  Khan Sharun; Ruchi Tiwari; Kuldeep Dhama; Talha Bin Emran; Ali A Rabaan; Abbas Al Mutair
Journal:  Hum Vaccin Immunother       Date:  2021-06-23       Impact factor: 3.452

8.  The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.

Authors:  Qianqian Li; Jiajing Wu; Jianhui Nie; Li Zhang; Huan Hao; Shuo Liu; Chenyan Zhao; Qi Zhang; Huan Liu; Lingling Nie; Haiyang Qin; Meng Wang; Qiong Lu; Xiaoyu Li; Qiyu Sun; Junkai Liu; Linqi Zhang; Xuguang Li; Weijin Huang; Youchun Wang
Journal:  Cell       Date:  2020-07-17       Impact factor: 41.582

9.  D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.

Authors:  Drew Weissman; Mohamad-Gabriel Alameh; Thushan de Silva; Paul Collini; Hailey Hornsby; Rebecca Brown; Celia C LaBranche; Robert J Edwards; Laura Sutherland; Sampa Santra; Katayoun Mansouri; Sophie Gobeil; Charlene McDanal; Norbert Pardi; Nick Hengartner; Paulo J C Lin; Ying Tam; Pamela A Shaw; Mark G Lewis; Carsten Boesler; Uğur Şahin; Priyamvada Acharya; Barton F Haynes; Bette Korber; David C Montefiori
Journal:  Cell Host Microbe       Date:  2020-12-01       Impact factor: 31.316

10.  Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.

Authors:  Leonid Yurkovetskiy; Xue Wang; Kristen E Pascal; Christopher Tomkins-Tinch; Thomas P Nyalile; Yetao Wang; Alina Baum; William E Diehl; Ann Dauphin; Claudia Carbone; Kristen Veinotte; Shawn B Egri; Stephen F Schaffner; Jacob E Lemieux; James B Munro; Ashique Rafique; Abhi Barve; Pardis C Sabeti; Christos A Kyratsous; Natalya V Dudkina; Kuang Shen; Jeremy Luban
Journal:  Cell       Date:  2020-09-15       Impact factor: 66.850

View more
  15 in total

Review 1.  Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.

Authors:  Cong Sun; Chu Xie; Guo-Long Bu; Lan-Yi Zhong; Mu-Sheng Zeng
Journal:  Signal Transduct Target Ther       Date:  2022-06-28

2.  Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from Alpha to Omicron.

Authors:  Chiranjib Chakraborty; Manojit Bhattacharya; Ashish Ranjan Sharma; Kuldeep Dhama; Sang-Soo Lee
Journal:  Geroscience       Date:  2022-07-13       Impact factor: 7.581

3.  SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells.

Authors:  Rayhane Nchioua; Annika Schundner; Dorota Kmiec; Caterina Prelli Bozzo; Fabian Zech; Lennart Koepke; Alexander Graf; Stefan Krebs; Helmut Blum; Manfred Frick; Konstantin M J Sparrer; Frank Kirchhoff
Journal:  J Virol       Date:  2022-05-11       Impact factor: 6.549

Review 4.  Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions.

Authors:  Fahadul Islam; Manish Dhawan; Mohamed H Nafady; Talha Bin Emran; Saikat Mitra; Om Prakash Choudhary; Aklima Akter
Journal:  Ann Med Surg (Lond)       Date:  2022-05-07

5.  A Paradigm Shift in the Combination Changes of SARS-CoV-2 Variants and Increased Spread of Delta Variant (B.1.617.2) across the World.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Govindasamy Agoramoorthy; Sang-Soo Lee
Journal:  Aging Dis       Date:  2022-06-01       Impact factor: 9.968

6.  Genomic surveillance of SARS-CoV-2 in Puerto Rico reveals emergence of an autochthonous lineage and early detection of variants.

Authors:  Gilberto A Santiago; Betzabel Flores; Glenda L Gonzalez; Keyla N Charriez; Limari Cora-Huertas; Hannah R Volkman; Steven Van Belleghem; Vanessa Rivera-Amill; Laura E Adams; Melissa Marzan; Lorena Hernandez; Iris Cardona; Eduardo O'Neill; Gabriela Paz-Bailey; Riccardo Papa; Jorge L Munoz-Jordan
Journal:  Res Sq       Date:  2022-01-20

7.  Eigenvalue analysis of SARS-CoV-2 viral load data: illustration for eight COVID-19 patients.

Authors:  Till D Frank
Journal:  Int J Data Sci Anal       Date:  2022-04-04

Review 8.  A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

9.  Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Bidyut Mallik; Shyam Sundar Nandi; Sang-Soo Lee
Journal:  Infect Genet Evol       Date:  2022-04-13       Impact factor: 4.393

Review 10.  Immune Response to SARS-CoV-2 Vaccines.

Authors:  Navya Bellamkonda; Upendra Pradeep Lambe; Sonali Sawant; Shyam Sundar Nandi; Chiranjib Chakraborty; Deepak Shukla
Journal:  Biomedicines       Date:  2022-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.